Duke University Medical Center Chooses Immucor's Galileo
NORCROSS, Ga., Feb. 9 /PRNewswire-FirstCall/ -- Immucor, Inc. , a global leader in providing automated instrument-reagent systems to the blood transfusion industry, announced today that it has received a purchase order for 2 Galileo systems from Duke University Medical Center.
Duke University Medical Center is consistently ranked among the top ten health care organizations in the country. As the youngest of the nation's leading medical centers, Duke has earned an international reputation for innovation and excellence. Duke will utilize Galileo's full test menu: Blood Typing, Weak D testing, Antibody Screening, Antibody Identification, Direct Antiglobulin testing, and Donor Retypes.
"Duke University Medical Center is one of the most prestigious health care organizations in the United States," stated Dr. Gioacchino De Chirico, President of Immucor, Inc. "We are very pleased that Duke has chosen the Galileo system for their blood bank laboratory."
Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of our market segments.
For more information on Immucor, please visit our website at http://www.immucor.com.
Statements contained in this press release that are not statements of historical fact are "forward-looking statements" as that term is defined under federal securities laws, including, without limitation, all statements concerning Immucor's expectations, beliefs, intentions or strategies for the future. Forward-looking statements may be identified by words such as "plans," "expects," "believes," "anticipates," "estimates," "projects," "will," "should" and other words of similar meaning. Investors are cautioned not to place undue reliance on any forward-looking statements. Our financial results may be adversely impacted by the inability of customers, including Duke University Medical Center, to effectively integrate our Galileo instruments into their blood testing operations. Further risks are detailed in the Company's filings with the Securities and Exchange Commission. Immucor assumes no obligation to update any forward-looking statements.Immucor, Inc.
CONTACT: Edward Gallup of Immucor, Inc., +1-770-441-2051
Web site: http://www.immucor.com/